PMID- 30657002
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20210507
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 26
IP  - 4
DP  - 2020 Apr
TI  - Minimal clinically important difference of improvement on the Arm Function in 
      Multiple Sclerosis Questionnaire (AMSQ).
PG  - 505-508
LID - 10.1177/1352458518823489 [doi]
AB  - BACKGROUND: The Arm Function in Multiple Sclerosis Questionnaire (AMSQ) has been 
      developed to assess upper extremity function of patients with multiple sclerosis 
      (MS). A minimal clinically important difference (MCID) value has not been 
      determined yet. OBJECTIVE: The objective of this study is to determine an MCID 
      for AMSQ. METHODS: We used the sensitivity- and specificity-based approach with 
      dichotomized global perceived effect as an anchor. RESULTS: The receiver 
      operating characteristic (ROC) curve yielded an optimal threshold value of 14.5 
      (sensitivity 0.68 and specificity 0.79). The area under the ROC curve value was 
      0.77. CONCLUSION: We identified an MCID of 15 points for the AMSQ (range 31-186).
FAU - van Munster, Caspar Ep
AU  - van Munster CE
AUID- ORCID: 0000-0001-8701-5413
AD  - Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam 
      UMC, Amsterdam, The Netherlands.
FAU - Kaya, Levent
AU  - Kaya L
AD  - Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam 
      UMC, Amsterdam, The Netherlands.
FAU - Obura, Morgan
AU  - Obura M
AD  - Department of Epidemiology and Biostatistics, Amsterdam Public Health Research 
      Institute, Amsterdam UMC, Amsterdam, The Netherlands.
FAU - Kalkers, Nynke F
AU  - Kalkers NF
AD  - Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam 
      UMC, Amsterdam, The Netherlands.
FAU - Uitdehaag, Bernard Mj
AU  - Uitdehaag BM
AD  - Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam 
      UMC, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190118
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Potassium Channel Blockers)
RN  - BH3B64OKL9 (4-Aminopyridine)
SB  - IM
MH  - 4-Aminopyridine/pharmacology
MH  - Adult
MH  - Arm/*physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - Multiple Sclerosis/*drug therapy/physiopathology
MH  - *Patient Reported Outcome Measures
MH  - Potassium Channel Blockers/*pharmacology
MH  - Psychometrics/instrumentation/*standards
MH  - Sensitivity and Specificity
PMC - PMC7140338
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - minimal clinically important difference
OT  - patient-reported outcome measure
OT  - upper extremity function
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: C.E.P.v.M. has received travel support from Novartis 
      Pharma AG, Sanofi Genzyme, and Teva Pharmaceuticals and honoraria for lecturing 
      and consulting from Biogen-Idec and Merck Serono. L.K. and M.O. have no conflicts 
      of interest. N.F.K. has received speaker and consultancy fees from Biogen, Teva, 
      Genzyme, Roche, and Novartis. B.M.J.U. has received consultancy fees from 
      Biogen-Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva.
EDAT- 2019/01/19 06:00
MHDA- 2021/05/08 06:00
PMCR- 2020/04/08
CRDT- 2019/01/19 06:00
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
PHST- 2019/01/19 06:00 [entrez]
PHST- 2020/04/08 00:00 [pmc-release]
AID - 10.1177_1352458518823489 [pii]
AID - 10.1177/1352458518823489 [doi]
PST - ppublish
SO  - Mult Scler. 2020 Apr;26(4):505-508. doi: 10.1177/1352458518823489. Epub 2019 Jan 
      18.